Ofatumumab versus Teriflunomide in Multiple Sclerosis
Articles > Article · 2020
Authors: Stephen L. Hauser, Amit Bar-Or, Jeffrey A. Cohen, Giancarlo Comi, Jorge Correale, Patricia K. Coyle, Anne H. Cross, Jerome de Seze, David Leppert, Xavier Montalban, Krzysztof Selmaj, Heinz Wiendl, Cecile Kerloeguen, Roman Willi, Bingbing Li, Algirdas Kakarieka, Davorka Tomic, Alexandra Goodyear, Ratnakar Pingili, Dieter A. Haring, Krishnan Ramanathan, Ayşe Nur YÜCEYAR, Ludwig Kappos
NEW ENGLAND JOURNAL OF MEDICINE, Journal Indexed in SCI Expanded, International, 2020, vol 383, pp 546-557
Summary
BackgroundOfatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known.